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Acute GVHD is the most important complication of allogeneic BMT, and its successful management is crucial to the outcome of treatment. First-line treatment of acute GVHD is usually corticosteroids. In a recent survey among EBMT centres, all of the 86 centres which reported their treatment practices used corticosteroids, usually methylprednisolone (MP), as first-line treatment. 1 However, the treatment is given variably. According to the survey, there were differences in the grade of GVHD which indicated treatment (any apparent acute GVHD vs grade II or more) as well as in the dosage. The most commonly used initial dose was 2 mg/kg/day intravenously, but a considerable proportion of the centres gave 5 mg/kg/day or more, and the initial dosage ranged between 1 and 20 mg/kg/day. At many centres the dose was dependent on the severity of GVHD.
It is not known whether an aggressive or more restrained use of corticosteroids is preferable. Acute GVHD might be controlled more effectively by giving corticosteroids early and in high doses. However, the untoward effects of corticosteroids are well-known; the possibility of increasing the risk of infections in these immunosuppressed patients must particularly be taken into account. On the other hand, GVHD, especially chronic GVHD, is known to be immunosuppressive, and effectively stopping the GVHD process might be advantageous for the recovery of the immunological system. Van Lint and co-workers 2 have recently published results of a randomized study indicating that treatment of acute GVHD with an initial dose of 10 mg/kg/day was not more effective than with a dose of 2 mg/kg/day. We have utilized the results of the EBMT survey and the EBMT registry database to discover the influence of intensity of corticosteroid treatment on the outcome of patients with acute GVHD.
Among the centres which participated in the survey, two clearly different groups were identified according to the intensity of the use of corticosteroids. Twelve centres treated only acute GVHD grade II or more and initially gave 2 mg/kg/day methylprednisolone irrespective of the severity of GVHD. Six centres treated acute GVHD at the first clinical signs likely to be caused by GVHD and gave 10 mg/kg/day or more. The outcome of all patients with chronic myeloid leukaemia treated at the two groups of centres was then recorded using the EBMT database. All these patients had been given GVHD prophylaxis with cyclosporin and a short course of methotrexate. There were 250 patients altogether treated at the centres using the less intense approach and 125 patients at the centres using the more intense policy. Figure 1 shows the survival of these two patient groups. The survival of patients treated at the centres giving less intensive corticosteroid treatment for acute GVHD was highly significantly (P = 0.00006, log rank test) better than that of patients treated at the centres giving more intense corticosteroid treatment. There was a non-significant trend towards a higher relapse rate in the intensively treated group (Figure 2) . Table 1 shows the principal causes of death. There were significantly more deaths due to infections in the more intensely treated group and also significantly more deaths from graft failure.
The present results indicate that intense treatment of acute GVHD with high doses of corticosteroids does not give better results than a more conventional approach with 2 mg/kg/day of MP. Survival seems to be even worse with the more intense treatment policy. These findings have, however, to be interpreted with caution. The number of centres, especially in the group using the more intense approach, was relatively limited, and a centre-related effect could at least partly explain the results obtained. There might have been other differences in the management of patients; for example, the prophylaxis of GVHD might have been different in various details. This, however, did not seem to be the case. According to the survey, there were no apparent differences in the dose of CsA or in other aspects of the prophylaxis. Differences may have existed in the subgroups of patients. Finally, the survey of practices of treatment of acute GVHD reflected the situation at the time of the survey, whereas the patients had been treated over a period of several years. It is possible that treatment policy could have changed during that time.
The over-representation of infections as causes of death among patients treated at centres using the more intense policy is to be expected. The registry data did not allow a more detailed analysis of the nature of the infections. The reason for more deaths from graft failure at the intensively treating centres is less obvious. A possible explanation might be a higher incidence of CMV infection which could, together with its treatment, be the cause of graft failure.
The present analysis included only patients with chronic myeloid leukaemia, but there is no obvious reason to assume that these findings would not also be applicable to patients with other diagnoses.
Due to the reservations mentioned, the present results can only be taken as suggestive. Nevertheless, they seem to indicate that intense high corticosteroid dose treatment of acute GVHD does not give better results than does a more conventional initial treatment with 2 mg/kg/day of MP for grade II or more, which is in accordance with the GITMO results.
2 High doses of corticosteroids may even lead to excessive side-effects and impaired survival.
